Joshua Cohen covers healthcare policy, with a special focus on prescription drug pricing and reimbursement. Cohen writes about a wide variety of topics, including weight loss drugs, the Inflation Reduction Act, and even things like health risks related to climate change.
Medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very popular as weight loss agents. Taken in accordance with the instructions on the label and an appropriate diet and exercise regimen, GLP-1s are effective at lowering a person’s weight.
If confirmed by the Senate as Secretary of HHS, Robert F. Kennedy Jr. wants to tackle high rates of diabetes and obesity through lifestyle modification, including dietary and other behavioral changes. Integral to his vision are plans to “fix” the food system.explains that despite some individuals being genetically predisposed to unhealthy weight gain, the majority of people can “modify the vectors of obesity” by incorporating healthier eating habits and more daily physical activity.
Kennedy told National Public Radio that Trump expects him to show “measurable impacts on a diminishment of chronic disease within two years.” Presumably this would include obesity, which may be a tall order. Positive results as a consequence of behavioral change are possible, but usually only after long periods of time.
With obesity prevention, the issue may be more difficult than Kennedy imagines, given the lengthy history of attempts to address it through federal government initiatives. The nutrition and physical activity problem in the U.S. has long been recognized. It’s one that administrations from Carter to Biden, have sought to address, but seemingly unsuccessfully.
RFK Jr. Obesity Obesity Prevention GLP-1S Ozempic Weight Loss Chronic Disease FDA HHS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
White House Wants Medicare, Medicaid to Cover GLP-1 DrugsIn its announcement, the Biden administration called anti-obesity medicines “life-saving drugs,” noting that they can also prevent diabetes.
Read more »
Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss MedsThe outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.
Read more »
Ozempic vs Supplements: Dietitian Reveals Truth About GLP-1 ImitationsThe Best in Science News and Amazing Breakthroughs
Read more »
Missteps and opportunities in the adoption of GLP-1 treatments.If you're in a relationship that faces struggles with weight and are considering GLP-1 medications like Ozempic, consider this proactive approach to communicating your goals.
Read more »
Food Retention With GLP-1s May Vary by Endoscopic ProcedureA study found that GLP-1 RA use is linked to risks for retained gastric contents during single endoscopic procedures but not with combined upper endoscopy and colonoscopy.
Read more »
To Hold or Not to Hold GLP-1s Before SurgeryDr Anne Peters discusses the conflicting recommendations from FDA and medical societies regarding managing patients on GLP-1s prior to elective surgery.
Read more »